I celebrated five years since my bone marrow transplant with a surprise video from my donor, a beautiful reminder of the life ...

An announcement from Moleculin Biotech ( ($MBRX) ) is now available. On July 9, 2025, Moleculin Biotech announced that the Regulation Agency for ...

Moleculin Biotech (MBRX) announced that the Regulation Agency for Medical and Pharmaceutical Activities, or RAMPA, in the country of Georgia has ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 ...

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, ...

Dr Luciano Nicosia, based at the Cancer Research UK Manchester Institute, will focus on developing more targeted therapies ...

Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX ...

T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive form of blood cancer that can occur in both children and ...

A panelist discusses how the ASCERTAIN-V study demonstrated that an all-oral combination of decitabine-cedazuridine plus ...

Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.

Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.